Omnibus VI: What the Proposed Changes Mean for the EU Cosmetics Regulation

eu omnibus and cosmetics regulation

What Is the EU Omnibus VI Package and Why Is It Significant for Cosmetics Legislation?

The European Commission’s Omnibus VI package is part of a broader initiative to simplify EU chemical legislation, reduce administrative burdens and improve the competitiveness of European industry.

Presented in July 2025, the package proposes amendments to several legislative instruments, including the EU Cosmetics Regulation (EC) No 1223/2009, the CLP Regulation and the Fertilising Products Regulation.

For the cosmetics sector, the changes concern several important aspects of regulatory compliance, particularly the treatment of substances classified as carcinogenic, mutagenic or toxic for reproduction (CMR), the use of nanomaterials and certain administrative procedures.

The initiative has attracted considerable attention because it seeks to simplify specific requirements while retaining the underlying framework for consumer safety.

As of November 2026, the legislative process has progressed substantially. The European Parliament approved the negotiated text on 22 October 2026, but the procedure is still awaiting the Council’s first-reading position. Consequently, the package should not yet be treated as fully adopted legislation.

For cosmetic manufacturers, responsible persons and regulatory affairs professionals, understanding the agreed changes at this stage is useful for planning future compliance activities. However, any implementation decision must continue to rely on the legislation currently applicable until the new Regulation enters into force and its provisions become applicable.

Why Did the European Commission Introduce Omnibus VI?

The Commission presented Omnibus VI as part of its programme to simplify and modernise EU chemical legislation.

The cosmetics industry operates within a detailed regulatory framework. Manufacturers must ensure that products comply with the Cosmetics Regulation, maintain a Product Information File (PIF), prepare a Cosmetic Product Safety Report (CPSR), notify products through the Cosmetic Products Notification Portal (CPNP), and comply with restrictions and prohibitions affecting individual ingredients.

These obligations serve different purposes, but certain procedures can create additional administrative work or overlap with other regulatory mechanisms.

The Commission’s proposal therefore sought to address specific areas where procedures could be streamlined without abandoning the fundamental requirements governing cosmetic product safety.

The package also forms part of a wider debate about the balance between regulatory simplification, industrial competitiveness and consumer protection.

Changes affecting the treatment of CMR substances have been particularly significant because they influence the time available to companies to reformulate products when an ingredient becomes prohibited.

It is important, however, to distinguish the original Commission proposal from the compromise negotiated by the European Parliament and Council. The final legislative outcome may differ from the initial proposal, and the agreed text is the relevant reference for anticipating the forthcoming rules.

How Does Omnibus VI Change the Rules for CMR Substances in Cosmetics?

One of the most significant elements for cosmetics concerns Article 15 of Regulation (EC) No 1223/2009. Under the existing framework, substances classified as CMR Category 1A, 1B or 2 under the CLP Regulation are generally prohibited in cosmetic products, subject to the specific derogation mechanism established by Article 15.

A derogation is not automatic. It requires the applicable scientific and regulatory conditions to be satisfied. In particular, the substance must be evaluated by the Scientific Committee on Consumer Safety (SCCS) and found safe for use in cosmetic products under the conditions considered.

The practical difficulty arises when a substance becomes subject to a prohibition and companies need to adapt their formulations, validate alternatives, update product documentation and manage existing stock.

The negotiated Omnibus VI text introduces more structured transition periods for affected cosmetic products. The agreed periods depend on whether a derogation is requested and, where applicable, why that request is refused. These periods reflect the compromise reported by the European Parliament and its research service.

The distinction between placing a product on the market and making it available on the market is important. The former concerns the first introduction of a product onto the EU market, while the latter also encompasses subsequent commercial supply.

The proposed approach recognises that companies may need time to reformulate products and manage existing distribution channels. At the same time, the duration of the transition depends on the regulatory circumstances rather than providing a single, universal grace period.

These provisions should not be interpreted as a general authorisation to continue using a CMR substance after a prohibition takes effect. They are specific transition arrangements whose application will depend on the final legal text and the relevant circumstances.

For manufacturers, the practical lesson is to maintain an up-to-date overview of ingredients potentially affected by harmonised classifications, including the status of any derogation procedure and the availability of suitable alternatives.

What Are the Article 16 Pre-Notification Requirements for Nanomaterials in Cosmetics?

close-up image of a black, metallic nanomaterial mesh

Another important area concerns cosmetic products containing nanomaterials, for which Article 16 of the Cosmetics Regulation establishes specific requirements.

These include a separate notification to the Commission, generally six months before the product is placed on the market, subject to the exceptions provided for in the Regulation. This requirement exists alongside the general product notification under Article 13 which is submitted through the CPNP.

The Commission’s original Omnibus VI proposal sought to remove the separate pre-notification requirement under Article 16, on the grounds that the process overlaps with information already provided through the general notification framework. However, the position changed during the legislative negotiations.

According to the European Parliament’s summary of the provisional agreement, the separate pre-market notification requirement for cosmetic products containing nanomaterials is retained.

This is a particularly important distinction for regulatory planning. Companies should not assume that the Omnibus VI package will eliminate the Article 16 process simply because that change appeared in the original Commission proposal.

Until the applicable legislation is amended, the existing requirements remain relevant. Manufacturers should continue to identify nanomaterials in their formulations, determine whether Article 16 applies and organise the necessary notification sufficiently in advance of market placement.

The retention of this procedure also reinforces the need to distinguish administrative simplification from the removal of substantive regulatory controls.

What Changes Does Omnibus VI Propose for Colourants, Preservatives and UV Filters?

The original Commission proposal also addressed procedures for incorporating certain ingredients into the relevant annexes of the Cosmetics Regulation, including colourants, preservatives and UV filters.

These annexes are central to cosmetics compliance:

  • Annex IV lists permitted colourants.
  • Annex V lists permitted preservatives.
  • Annex VI lists permitted UV filters.

The use of an ingredient in one of these functional categories is subject to the applicable conditions, including any restrictions on concentration, product type or conditions of use.

Streamlining the procedure for updating these annexes could help improve regulatory efficiency when new ingredients are evaluated or existing entries need to be amended. However, a proposal to simplify a procedure does not mean that a new ingredient becomes automatically permitted or that the existing safety requirements disappear.

Companies should therefore avoid treating the Omnibus VI initiative as a general relaxation of the rules governing cosmetic ingredients. The relevant annex entry and the applicable conditions must still be checked for each product.

For regulatory affairs teams, the more practical question is whether the final text introduces a concrete procedural change that affects how an ingredient can be authorised or how an amendment to an annex is processed. That determination requires reference to the final published Regulation rather than the initial proposal or an industry summary.

What Will Remain Unchanged for Cosmetics Manufacturers Under Omnibus VI?

Although Omnibus VI is intended to simplify selected requirements, it does not replace the fundamental structure of the Cosmetics Regulation. The responsible person will continue to be responsible for ensuring compliance with the applicable requirements.

Manufacturers must continue to operate appropriate quality systems, use suitable ingredients, manufacture products under good manufacturing practice and ensure that the safety assessment is supported by adequate information.

In particular, companies should not interpret the package as removing the need for:

  • A CPSR prepared in accordance with Annex I.
  • A PIF containing the required product information.
  • CPNP notification before placing a cosmetic product on the market.
  • Compliance with applicable restrictions and prohibitions in the annexes.
  • Appropriate evidence supporting product safety and claims.
  • Good manufacturing practice, including the relevant requirements of Article 8.

Nor should a transition period be confused with an exemption from the safety obligations that apply during the period. The final text must be examined carefully to determine the precise scope of each amendment, its application date and any conditions attached to it.

What Should Cosmetics Companies Do Now To Prepare for Omnibus VI?

a white question mark painted on a wall

With the European Parliament having approved the negotiated text on 22 October 2026, companies have a useful opportunity to prepare for the likely regulatory changes while continuing to comply with the current rules.

A proportionate approach would involve four steps:

First, review the ingredient portfolio. Identify substances that may be affected by current or anticipated CMR classifications. Record the applicable classification, the relevant cosmetic restriction and any derogation considerations.

Second, review reformulation planning. Where an ingredient may become prohibited, assess the availability of alternatives, the technical feasibility of reformulation and the time required for stability, compatibility and safety assessments. The transition periods under Omnibus VI should be considered only once their final legal scope and applicability have been confirmed.

Third, maintain nanomaterial compliance. Continue to follow the existing Article 16 requirements unless and until an applicable legislative amendment changes them. The negotiated Omnibus VI text retains the separate pre-market notification procedure.

Fourth, monitor formal adoption and publication. The European Parliament’s approval is an important milestone, but the Council must complete the relevant legislative steps before the Regulation can be published and enter into force. Companies should then examine the final text, including its entry-into-force and application provisions.

This last point is essential because different provisions may have different practical consequences and dates of application. 

What Does Omnibus VI Mean for the Future of EU Cosmetics Regulation?

Omnibus VI represents an important development in the evolution of EU chemicals and cosmetics legislation. Its proposed changes seek to reduce selected administrative burdens and introduce more structured transition arrangements for cosmetic products affected by CMR prohibitions.

For cosmetics, the agreed approach includes differentiated transition periods depending on the circumstances of a derogation request, while retaining the separate pre-market notification requirement for nanomaterials.

The package should therefore be understood as a targeted revision of particular procedures, rather than a wholesale rewriting of the Cosmetics Regulation.

For manufacturers and responsible persons, the immediate priority is to prepare for the likely changes without prematurely applying provisions that have not yet become legally effective.

Monitoring the final adoption, reviewing affected ingredients and maintaining robust product documentation will help companies respond efficiently once the new rules become applicable.

Delegating this aspect to experts tracking the changes in real time is what makes a brand well-prepared for market expansion or fail due to lack of compliance. 

Key Takeaways: EU Omnibus VI and Changes to Cosmetics Regulation

  • Omnibus VI proposes targeted changes to the EU Cosmetics Regulation to reduce administrative burdens while maintaining consumer safety requirements.
  • The negotiated text introduces differentiated transition periods for cosmetic products affected by CMR prohibitions, depending on the circumstances of a derogation request.
  • The separate pre-market notification requirement for nanomaterials under Article 16 is retained.
  • The existing requirements for CPSRs, PIFs, CPNP notifications, ingredient restrictions and good manufacturing practice remain in place.
  • The European Parliament approved the negotiated text on 22 October 2026, but the legislative process is not yet complete.
  • Manufacturers and responsible persons should review affected ingredients, assess reformulation needs and monitor formal adoption before applying the new provisions.

You might also like...